FDA.reportPublic FDA data

CABOZANTINIB S-MALATE - Food and Drug Administration

Set ID
ade5b235-a9b4-e445-bdbd-7d75ec61ea16
Type
Indexing - Product Concept
Effective date
2014-05-08
Version
1
Source
DailyMed source

Mapped DailyMed Labels#

Label, Relation, Manufacturer table
LabelRelationManufacturerEffective
These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012Product nameExelixis, Inc. | Patheon Inc. | Rottendorf Pharma GmbH2025-10-19
These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ. COMETRIQ ® (cabozantinib) capsules, for oral use Initial U.S. Approval: 2012Product nameExelixis, Inc. | Catalent CTS, LLC2025-10-18
These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012Product nameExelixis, Inc. | Patheon Inc. | Rottendorf Pharma GmbH2025-09-14
These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ. COMETRIQ ® (cabozantinib) capsules, for oral use Initial U.S. Approval: 2012Product nameExelixis, Inc. | Catalent CTS, LLC2025-02-04